Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH

Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies. The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug…

Read More

THCB Gang Episode 14, Friday November 14

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday November 14 at 1PM PT 4PM ET. Today we have also a special guest – former Permanente Medical Group CEO Dr Robbie Pearl @robertpearlmd. Robbie has been diving into AI in his latest book ChatGPT-MD and we’ll be chatting about that as well as his forecasts for health…

Read More